Prosecution Insights
Prosecution Insights
30 pending office actions • 16 art units • 27 examiners • 0 of 30 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 13 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 13 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (3%) |
| §103 only | 11 (37%) |
| §112 only | 4 (13%) |
| Double-patenting only | 1 (3%) |
| Double-patenting + other | 1 (3%) |
| Multi-statute (no §101) | 10 (33%) |
| No statute on record | 2 (7%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RICCI, CRAIG D | 3 | 53.5% | +52.6% |
| FREDRICKSON, COURTNEY B | 2 | 75.7% | +30.9% |
| JANOSKO, CHASITY PAIGE | 1 | 17.5% | +77.8% |
| BAEK, BONG-SOOK | 1 | 41.7% | +69.8% |
| BASQUILL, SEAN M | 1 | 38.8% | +21.6% |
| AZPURU, CARLOS A | 1 | 83.8% | +10.6% |
| CRAIGO, BAHAR ALAWI | 1 | 46.9% | +27.1% |
| BERKE-SCHLESSEL, DAVID W | 1 | 66.6% | +31.9% |
| DAVISON, LAURA L | 1 | 32.6% | +36.2% |
| ZIMMERMAN, REBECCA LYNEE | 1 | 79.0% | +18.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18304884 | IMPLANT IDENTIFICATION BY RADIOGRAPHIC MEANS | ZIMMERMAN, REBECCA LYNEE | 46d overdue |
| 18733551 | BROMODOMAIN INHIBITORS | CHEN, PO-CHIH | 19d overdue |
| 18666929 | SYSTEMS AND METHODS FOR GENERATING LONGITUDINAL DATA PROFILES FROM MULTIPLE DATA SOURCES | KIM, STEVEN S | 15d overdue |
| 17787828 | Protein Tyrosine Phosphatase Degraders and Methods of Use Thereof | VALLE, ERNESTO | 7d |
| 18476916 | METHODS OF TREATING HIDRADENITIS SUPPURATIVA | RZECZYCKI, PHILLIP MATTHEW | 9d |
| 18572741 | Degrader Compounds and Uses Thereof | SHIAO, REI TSANG | 22d |
| 18599800 | USE OF ALPHA-2-ADRENERGIC RECEPTOR AGONISTS FOR IMPROVING VISION | AZPURU, CARLOS A | 27d |
| 18972793 | USE OF BOTULINUM TOXINS FOR THE TREATMENT OF PLATYSMA PROMINENCE | JANOSKO, CHASITY PAIGE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18304884 | IMPLANT IDENTIFICATION BY RADIOGRAPHIC MEANS | ZIMMERMAN, REBECCA LYNEE | 46d overdue |
| 17325900 | METHODS OF TREATING HEAVY MENSTRUAL BLEEDING | RICCI, CRAIG D | 13d |
| 18431278 | DUAL CAP SYSTEM FOR CONTAINER-CLOSURES TO MAINTAIN TIP STERILITY DURING SHELF STORAGE | DAVISON, LAURA L | 22d |
| 18599800 | USE OF ALPHA-2-ADRENERGIC RECEPTOR AGONISTS FOR IMPROVING VISION | AZPURU, CARLOS A | 27d |
| 19417018 | SODIUM CHLORITE COMPOSITIONS WITH ENHANCED ANTI-MICROBIAL EFFICACY AND REDUCED TOXICITY | RICCI, CRAIG D | — |
| 18972793 | USE OF BOTULINUM TOXINS FOR THE TREATMENT OF PLATYSMA PROMINENCE | JANOSKO, CHASITY PAIGE | — |
| 18813414 | PHARMACEUTICAL COMPOSITIONS COMPRISING (3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL | BAEK, BONG-SOOK | — |
| 18611454 | OCULAR IMPLANT MADE BY A DOUBLE EXTRUSION PROCESS | BASQUILL, SEAN M | — |
| Art Unit | Apps |
|---|---|
| 1611 | 4 |
| 1623 | 4 |
| 1617 | 2 |
| 3774 | 2 |
| 1614 | 1 |
| 1699 | 1 |
| 1651 | 1 |
| 3993 | 1 |
| 1621 | 1 |
| 3698 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19417018 | SODIUM CHLORITE COMPOSITIONS WITH ENHANCED ANTI-MICROBIAL EFFICACY AND REDUCED TOXICITY | RICCI, CRAIG D | 1611 | §102DP | Non-Final OA | — | Pending | Dec 11, 2025 |
| 18972793 | USE OF BOTULINUM TOXINS FOR THE TREATMENT OF PLATYSMA PROMINENCE | JANOSKO, CHASITY PAIGE | — | §103 | Non-Final OA | — | Pending | Dec 06, 2024 |
| 18813414 | PHARMACEUTICAL COMPOSITIONS COMPRISING (3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL | BAEK, BONG-SOOK | — | §103 | Non-Final OA | — | Pending | Aug 23, 2024 |
| 18611454 | OCULAR IMPLANT MADE BY A DOUBLE EXTRUSION PROCESS | BASQUILL, SEAN M | 1614 | §103§112 | Non-Final OA | — | Pending | Mar 20, 2024 |
| 18599800 | USE OF ALPHA-2-ADRENERGIC RECEPTOR AGONISTS FOR IMPROVING VISION | AZPURU, CARLOS A | 1617 | §102§103Other | Non-Final OA | 27d | Pending | Mar 08, 2024 |
| 18582331 | DERMAL FILLER COMPOSITIONS | CRAIGO, BAHAR ALAWI | 1699 | DP | Non-Final OA | — | Pending | Feb 20, 2024 |
| 18437633 | NON-PROTEIN CLOSTRIDIAL TOXIN COMPOSITIONS | BERKE-SCHLESSEL, DAVID W | 1651 | §103§112Other | Non-Final OA | — | Pending | Feb 09, 2024 |
| 18431278 | DUAL CAP SYSTEM FOR CONTAINER-CLOSURES TO MAINTAIN TIP STERILITY DURING SHELF STORAGE | DAVISON, LAURA L | 3993 | §103Other | Non-Final OA | 22d | Pending | Feb 02, 2024 |
| 18304884 | IMPLANT IDENTIFICATION BY RADIOGRAPHIC MEANS | ZIMMERMAN, REBECCA LYNEE | 3774 | §102§103 | Non-Final OA | 46d overdue | Pending | Apr 21, 2023 |
| 17789162 | CROSSLINKED HA-COLLAGEN HYDROGELS AS DERMAL FILLERS | ISNOR, ALEXANDRA NICOLE | 1611 | §103Other | Final Rejection | 16d overdue | Pending | Jun 24, 2022 |
| 17515228 | TISSUE EXPANSION DEVICE | MANNAN, MIKAIL A | 3774 | §103 | Final Rejection | — | Pending | Oct 29, 2021 |
| 19189086 | RISANKIZUMAB COMPOSITIONS | FAY, ZOHREH ALEMZADEH | 1617 | §103 | Non-Final OA | — | Pending | Apr 24, 2025 |
| 18809439 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | WILSON, JERICA KATLYNN | — | §103 | Non-Final OA | — | Pending | Aug 20, 2024 |
| 18753308 | DEVICES AND METHODS FOR DELIVERING A BENEFICIAL AGENT TO A USER | FREDRICKSON, COURTNEY B | — | §112 | Non-Final OA | — | Pending | Jun 25, 2024 |
| 18733551 | BROMODOMAIN INHIBITORS | CHEN, PO-CHIH | 1621 | §103§112Other | Non-Final OA | 19d overdue | Pending | Jun 04, 2024 |
| 18666929 | SYSTEMS AND METHODS FOR GENERATING LONGITUDINAL DATA PROFILES FROM MULTIPLE DATA SOURCES | KIM, STEVEN S | 3698 | §101§103§112 | Non-Final OA | 15d overdue | Pending | May 17, 2024 |
| 18627239 | DOSING REGIMENS FOR USE IN PREVENTING RELAPSE OF ACUTE MYELOID LEUKEMIA FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH VENETOCLAX IN COMBINATION WITH AZACITIDINE | GALSTER, SAMUEL LEONARD | — | §103 | Non-Final OA | — | Pending | Apr 04, 2024 |
| 18590729 | SELECTIVE REDUCTION OF ANTIBODIES | VAN DRUFF, SYDNEY | — | §102§103 | Non-Final OA | — | Pending | Feb 28, 2024 |
| 18572741 | Degrader Compounds and Uses Thereof | SHIAO, REI TSANG | 1691 | §102§103Other | Non-Final OA | 22d | Pending | Dec 20, 2023 |
| 18489058 | DEVICES AND METHODS FOR DELIVERING A BENEFICIAL AGENT TO A USER | FREDRICKSON, COURTNEY B | 3783 | §112 | Non-Final OA | — | Pending | Oct 18, 2023 |
| 18482794 | COCRYSTALS OF UPADACITINIB | MOTEVALLI, OROD | 1628 | §112 | Final Rejection | — | Pending | Oct 06, 2023 |
| 18476916 | METHODS OF TREATING HIDRADENITIS SUPPURATIVA | RZECZYCKI, PHILLIP MATTHEW | 1625 | §102§103§112 | Non-Final OA | 9d | Pending | Sep 28, 2023 |
| 18462918 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | NOLAN, JASON MICHAEL | 1623 | Other | Final Rejection | 118d overdue | Pending | Sep 07, 2023 |
| 18317725 | METHODS OF TREATING HEAVY MENSTRUAL BLEEDING | RICCI, CRAIG D | 1611 | §103Other | Non-Final OA | — | Pending | May 15, 2023 |
| 17995798 | METHODS OF TREATING DIABETIC KIDNEY DISEASE | SCHACHERMEYER, SAMANTHA LYNN | 1693 | §102§103 | Final Rejection | — | Pending | Oct 07, 2022 |
| 17787828 | Protein Tyrosine Phosphatase Degraders and Methods of Use Thereof | VALLE, ERNESTO | 1623 | §102§112 | Non-Final OA | 7d | Pending | Jun 21, 2022 |
| 17807292 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CHENG, KAREN | 1623 | §103 | Final Rejection | 146d overdue | Pending | Jun 16, 2022 |
| 17446807 | PRODRUG MODULATORS OF THE INTEGRATED STRESS PATHWAY | SHTERENGARTS, SAMANTHA L | 1623 | §112 | Non-Final OA | — | Pending | Sep 02, 2021 |
| 17325900 | METHODS OF TREATING HEAVY MENSTRUAL BLEEDING | RICCI, CRAIG D | 1611 | Other | Non-Final OA | 13d | Pending | May 20, 2021 |
| 18361179 | ANTI-GARP-TGF-BETA1/PD-1 COMBINATION THERAPY | HAMA, JOANNE | 1647 | §103 | Non-Final OA | 28d | Pending | Jul 28, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial